NCT05277571View on ClinicalTrials.gov

A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

273

Participants

Timeline

Start Date

March 7, 2022

Primary Completion Date

July 17, 2025

Study Completion Date

September 19, 2025

Conditions
Atopic Dermatitis
Interventions
BIOLOGICAL

UCB1381

UCB1381 will be administered intravenously (iv) or subcutaneously (sc) in different dosages in Part A and iv in Part B

DRUG

Placebo

Placebo will be administered iv or sc in Part A and iv in Part B to maintain the blinding.

Trial Locations (16)

10029

Up0110 107, New York

19103

Up0110 119, Philadelphia

27103

Up0110 124, Winston-Salem

30349

Up0110 111, College Park

33014

Up0110 109, Miami Lakes

33705

Up0110 102, St. Petersburg

33765

Up0110 108, Clearwater

34471

Up0110 106, Ocala

55455

Up0110 114, Minneapolis

73170

Up0110 104, Oklahoma City

90045

Up0110 116, Los Angeles

90212

Up0110 125, Beverly Hills

91206

Up0110 101, Glendale

91324

Up0110 121, Northridge

91355

Up0110 127, Valencia

92780

Up0110 126, Tustin

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY